Announcement on stabilization measures in OssDsign AB (publ) during the period from May 31 to June 7, 2019
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR OTHER COUNTRIES WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE PERMITTED OR REQUIRE REGISTRATION OR OTHER MEASURES
Erik Penser Bank AB (”EPB”) announces that stabilization measures have been undertaken in OssDsign AB’s (publ) (”OssDsign” or the ”Company”) shares on Nasdaq First North.
As announced in connection with the offer to acquire newly issued shares in the Company and the listing of the Company's shares on Nasdaq First North (the "Offer"), EPB has the possibility, in its capacity as stabilization manager, to carry out transactions in order to support the market price of the shares at a higher level than what might otherwise prevail in the market.
Stabilization measures can be undertaken on Nasdaq First North, the OTC market or otherwise, and can be carried out at any time during the period starting on the first day of trading in the shares on Nasdaq First North, that is, May 24, 2019, and ending no later than 30 calendar days thereafter. However, EPB has no obligation to undertake any stabilization measures, and has not provided any guarantees that stabilization measures will be undertaken. Stabilization measures that have been initiated may be discontinued at any time without prior notice. Under no circumstances may transactions be carried out at a price that is higher than the price in the Offer.
Moreover, OssDsign has, within the Offer, issued an option to EPB, which may be exercised in whole or in part, to subscribe for 825,000 newly issued shares in the Company, corresponding to a maximum of 15 percent of the number of newly issued shares in the Offer, at a price corresponding to the price in the Offer, SEK 27.50, to cover any over-allotment in connection with the Offer.
EPB has, in its capacity as stabilization manager, announced that stabilization measures have been undertaken, in accordance with Article 5(4) of the EU Market Abuse Regulation 596/2014, on Nasdaq First North, as below. Contact person at EPB is Oskar Ekman, tel: +46 8 463 80 36.
Issuer: OssDsign AB (publ)
Securities: Shares (ISIN SE0012570448)
Offer size: 6,325,000 shares of which stabilization constitutes a maximum of 825,000 shares
Offer price: 27.50 SEK per share
Stabilization manager: Erik Penser Bank AB (publ)
Below is a summary of the stabilization transactions that have been undertaken during the period from May 31 to June 7, 2019. All transactions during the stabilization period have been undertaken on Nasdaq First North.
|Date||Quantity||Price (volume weighted average)||Price (lowest)||Price (highest)||Marketplace|
|2019-05-31||14,614||21.6158||21.000||22.000||Nasdaq First North|
|2019-06-03||12,507||22.0532||21.400||22.600||Nasdaq First North|
|2019-06-04||15,500||22.2839||22.000||22.600||Nasdaq First North|
|2019-06-05||61,089||23.9590||23.400||24.600||Nasdaq First North|
|2019-06-07||16,216||23,6008||23.000||24.400||Nasdaq First North|
The Company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: email@example.com.
For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Tel: +46 73 206 98 08, email: firstname.lastname@example.org
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.
This information is information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 18:00 CET on June 7, 2019